secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2026-08-06T20:08:36+00:00
Accession:  0001628280-26-054294
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion Q2 2026 revenue $125.8M (+11% YoY); net loss $(13.5M) vs prior year net income
--------------------------------------------------------------------------------

- Revenue $125.8M, up 11% GAAP (9% constant currency) YoY; net loss $(13.5M) or $(0.28)/share vs net income $1.3M in Q2 2025.
- Non-GAAP net income $6.3M ($0.13/share) vs $10.7M ($0.24/share) in Q2 2025; adjusted EBITDA $26.4M, up 7% YoY.
- On-X revenue grew 18% constant currency; stent grafts grew 12% constant currency; AMDS and NEXUS highlighted.
- Received U.S. FDA PMA approval for AMDS Hybrid Prosthesis; completed acquisition of Endospan Ltd. in May 2026.
- Reiterated FY2026 revenue guidance $480-496M (7-11% constant currency growth) and adjusted EBITDA $92-99M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000162828026054294/0001628280-26-054294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000162828026054294/aort-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-054294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer